Betamethasone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if corticosteroid injection modifies the natural course of de Quervain tendinopathy compared to a toradol injection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OrthoCarolina Research Institute, Inc.
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Epinephrine; Epinephryl borate; Ketorolac; Ketorolac Tromethamine; Lidocaine; Racepinephrine

Criteria

Inclusion Criteria:

• Diagnosis of DeQuervain tendinopathy

• Understands the local language and is willing and able to follow the requirements of the protocol

• Understands the informed consent and signs the institutional review board/independent ethics committee (IRB/IEC) approved informed consent form

Exclusion Criteria:

• Patients who have an allergy to lidocaine, celestone, or ketorolac, nonsteroidal anti-inflammatory drugs (NSAIDs), or acetylsalicylic acid (ASA)

• Patients who have an adverse reaction to lidocaine, celestone, or ketorolac (such as severe elevation of blood sugars in diabetics that caused medical complication)

• Patients who have received a prior steroid injection within the past three months

• Patients who have had a prior ipsilateral surgery for DeQuervain Tenosynovitis

• Patients that have a skin lesion at the location of injection (such as trauma, eczema, rash)

• Patients who have a current infection at the location of injection

• Patients who have had iontophoresis within three months

• Patients who are breast feeding, pregnant, or who plan to become pregnant in the next six months